A novel imidazo[1,5-b]isoquinolinone derivative, U63A05, inhibits Syk activation in mast cells to suppress IgE-mediated anaphylaxis in mice

Journal of Pharmacological Sciences

Volumn 115, Issue 4, 2011, Pages 500-508

  Kim, Do Kyun ^a   Lee, Jun Ho ^a   Kim, Jie Wan ^a   Kim, Hyuk Soon ^a   Kim, A Ram ^a   Kim, Bo Kyung ^a   Yi, Kyu Yang ^b   Park, Hye Jin ^c   Park, Dong Ki ^c   Choi, Wahn Soo ^a  

^a Konkuk University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

3 butyl 1 chloro 8 (2 methoxycarbonyl)phenyl 5H imidazo 1,5 b isoquinolin 10 one (U63A05); IgE; Mast cell; Syk; Type I hypersensitive response

Indexed keywords

3 BUTYL 1 CHLORO 8 ( 2 METHOXYCARBONYL)PHENYL 5H IMIDAZO[1,5 B]ISOQUINOLIN 10 ONE; ANTIALLERGIC AGENT; CETIRIZINE; IMMUNOGLOBULIN E; INTERLEUKIN 4; ISOQUINOLINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN KINASE SYK; STRESS ACTIVATED PROTEIN KINASE; THAPSIGARGIN; TUMOR NECROSIS FACTOR ALPHA; U 63A05; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MALE; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; PROTEIN EXPRESSION; RAT;

EID: 79955026300     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10300FP     Document Type: Article

References (32)

1. Georas SN, Guo J, De Fanis U, Casolaro V. T-helper cell type-2 regulation in allergic disease. Eur Respir J. 2005;26:1119-1137. (Pubitemid 41829946)
2. Metzger H. The high affinity receptor for IgE, FcepsilonRI. Novartis Found Symposium. 2004;257:51-59.
3. Beaven MA. Our perception of the mast cell from Paul Ehrlich to now. Eur J Immunol. 2009;39:11-25.
4. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol. 2006;117:1214-1225. (Pubitemid 43795719)
5. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454:445-454.
6. Kinet JP. The essential role of mast cells in orchestrating inflammation. Immunol Rev. 2007;217:5-6.
7. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10:387-402.
8. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev. 2009;228:149-169.
9. Bradding P. Novel approaches to the inhibition of mast cells in allergic disease. Clin Exp Allergy. 2008;38:704-708. (Pubitemid 351550672)
10. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8:218-230. (Pubitemid 351323290)
11. Kim JW, Lee JH, Hwang BY, Mun SH, Ko NY, Kim DK, et al. Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hyperpersensitivity response in vivo. Biochem Pharm. 2009;77:1506-1512.
12. Jensen BM, Swindle EJ, Iwaki S, Gilfillan AM. Generation, isolation, and maintenance of rodent mast cells and mast cell lines. Curr Protoc Immunol. 2006;3:3-23.
13. Ozawa K, Szallasi Z, Kazanietz MG, Blumberg PM, Mischak H, Mushinski JF, et al. Ca(2+)-dependent and Ca(2+)-independent isozymes of protein kinase C mediate exocytosis in Antigen-stimulated rat basophilic RBL-2H3 cells. Reconstitution of secretory responses with Ca2+ and purified isozymes in washed permeabilized cells. J Biol Chem. 1993;268:1749-1756.
14. Yoo SE, Shin YA, Lee SH, Kim NJ. The conformation and activity relationship of fused analogs of DuP753. Bioorg Med Chem. 1995;3:289-295.
15. Theoharides TC, Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann N Y Acad Sci. 2006;1088:78-99. (Pubitemid 47092046)
16. Ali H, Christensen SB, Foreman JC, Pearce FL, Piotrowski W, Thastrup O. The ability of Tg and thapsigargicin to activate cells involved in the inflammatory response. Br J Pharmacol. 1985;85:705-712. (Pubitemid 15028813)
17. Chu DH, Morita CT, Weiss A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol Rev. 1998;165:167-180. (Pubitemid 28524211)
18. Law CL, Chandran KA, Sidorenko SP, Clark EA. Phospholipase C-gamma1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. Mol Cell Biol. 1996;16:1305-1315.
19. Lorentz A, Klopp I, Gebhardt T, MannsMP, Bischoff SC. Role of activator protein 1, nuclear factor-kB, and nuclear factor of activated T cells in IgE receptormediated cytokine expression in mature human mast cells. J Allergy Clin Immunol. 2003;111:1062-1068. (Pubitemid 36570867)
20. Frossi B, Rivera J, Hirsch E, Pucillo C. Selective activation of Fyn/PI3K and p38 MAPK regulates IL-4 production in BMMC under nontoxic stress condition. J Immunol. 2007;178:2549-2555. (Pubitemid 46233457)
21. Stone KD, Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy and Clin Immunol. 2010;125:S73-S80.
22. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459-465. (Pubitemid 40341694)
23. Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91:160-167. (Pubitemid 36999475)
24. Poole JA, Matangkasombut P, Rosenwasser LJ. Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy. J Allergy Clin Immunol. 2005;115:S376-S385.
25. Masuda ES, Schmitz. Syk inhibitors as treatment for allergic rhinitis. Pulm Pharmacol Ther. 2008;21:461-467.
26. Meltzer EO, Berkowitz RB, Grossbard EB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol. 2005;115:791-796.
27. Roth K, Chen WM, Lin TJ. Positive and negative regulatory mechanisms in high-affinity IgE receptor-mediated mast cell activation. Arch Immunol Ther Exp (Warsz). 2008;56:385-399.
28. Parravinci V, Gadina M, Kovarova M, Odom S, Gonzalez-Espinosa C, Furumoto Y, et al. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol. 2002;3:741-748.
29. Hong H, Kitaura J, Xiao W, Horejsi V, Ra C, Lowell CA, et al. The Src family kinase Hck regulates mast cell activation by suppressing an inhibitory Src family kinase Lyn. Blood. 2007;110:2511-2519. (Pubitemid 47523173)
30. Lee JH, Mun SH, Ko NY, Kim JW, Kim DK, Kim JD, et al. Role of Src-family kinase isoforms, Lyn, Fyn, Fgr, and c-Src on degranulation RBL-2H3 mast cells. J Life Sci. 2007;17:350-355.
31. Kabu K, Yamasaki S, Kamimura D, Ito Y, Hasegawa A, Sato E, et al. Zinc is required for FcεRI-mediated mast cell activation. J Immunol. 2006;177:1296-1305. (Pubitemid 44036636)
32. Inagaki N, Nagai H. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment:mouse models for the development of remedies for human allergic dermatitis. J Pharmacol Sci. 2009;110:251-259.